Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3Tumor-Agnostic 2Genitourinary 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
etaracizumab × Tumor-Agnostic × Clear all
NCT00263783 2009-01-29

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

MedImmune LLC

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT00284817 2008-05-29

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

MedImmune LLC

Phase 1/2 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡